Oxford, United Kingdom
Enara Bio, founded in 2016 and headquartered in the United Kingdom, is carving a niche in the Biotechnology and Health Care sectors by focusing on unconventional cancer immunotherapy. With their slogan, "Advancing cancer immunotherapy by targeting the unconventional," the company aims to revolutionize treatments for solid tumors.
Enara Bio's pioneering efforts are powered by their proprietary EDAPT® and EnTiCE platforms. The EDAPT® platform enables the discovery of cancer-specific antigens from genomic 'dark matter,' creating a valuable library of Dark Antigens for novel therapeutic targeting. Concurrently, the EnTiCE platform is advancing programmable bispecific T cell engagers.
The company has attracted substantial industry collaboration and investment. In October 2024, Enara Bio secured a $32.50 million Series B round with support from top-tier backers like RA Capital Management, SV Health Investors, MERL Ventures Fund, Samsara BioCapital, Pfizer Venture Investments, and The Francis Crick Institute. Their strategic partnership with Boehringer Ingelheim further solidifies their potential to create novel, impactful cancer immunotherapies.
